Citations 1
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
Szlosarek, Peter W. , Moulec, Sylvestre Le , Popat, Sanjay , Planchard, David , Scherpereel, Arnaud , Jahan, Thierry, Koczywas, Marianna , Peikert, Tobias, Campbell, Carly , Sapir, I., McDonald, Alice , Oei, Coreen, Clawson, Alicia, Roche, Maria , Popat, Sanjay , Zauderer, Marjorie G. , Taylor, Paul D. , Forster, Martin D , Cameron, Robert Bruce , Fennell, Dean Anthony
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8515-8515
